InflaRx (NASDAQ:IFRX) Research Coverage Started at Needham & Company LLC

Needham & Company LLC started coverage on shares of InflaRx (NASDAQ:IFRX) in a research report released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $8.00 price target on the stock.

Several other equities analysts also recently weighed in on IFRX. Cantor Fitzgerald lifted their target price on InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday, June 24th. Finally, Zacks Research cut shares of InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $7.43.

InflaRx Trading Up 1.0%

Shares of IFRX stock opened at $2.04 on Monday. InflaRx has a 12-month low of $0.80 and a 12-month high of $2.95. The stock has a market capitalization of $300.63 million, a P/E ratio of -3.52 and a beta of 2.52. The firm’s 50 day moving average is $2.00 and its 200 day moving average is $1.78.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.04). As a group, equities analysts predict that InflaRx will post -0.31 earnings per share for the current year.

Institutional Investors Weigh In On InflaRx

Institutional investors and hedge funds have recently modified their holdings of the stock. Sanctuary Advisors LLC bought a new position in shares of InflaRx during the second quarter worth $25,000. AXQ Capital LP bought a new stake in InflaRx in the 2nd quarter valued at $41,000. ADAR1 Capital Management LLC purchased a new stake in InflaRx in the 1st quarter worth $142,000. DCF Advisers LLC purchased a new stake in InflaRx in the 4th quarter worth $160,000. Finally, T3 Companies LLC bought a new position in shares of InflaRx during the 4th quarter valued at about $294,000. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company’s research centers on the complement system, an important part of the immune response, with particular emphasis on blocking the activity of complement component C5a, which can contribute to excessive inflammation and tissue damage.

InflaRx’s lead product candidate is vilobelimab, a monoclonal antibody designed to selectively inhibit C5a while preserving other aspects of the complement system.